Your browser is no longer supported. Please, upgrade your browser.
Actinium Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.15 Insider Own1.61% Shs Outstand19.03M Perf Week-2.74%
Market Cap134.92M Forward P/E- EPS next Y-1.37 Insider Trans0.00% Shs Float13.38M Perf Month-6.34%
Income-22.20M PEG- EPS next Q-0.29 Inst Own17.00% Short Float6.46% Perf Quarter-23.35%
Sales- P/S- EPS this Y58.40% Inst Trans-0.74% Short Ratio3.18 Perf Half Y-37.64%
Book/sh3.50 P/B2.03 EPS next Y0.00% ROA- Target Price- Perf Year31.44%
Cash/sh3.80 P/C1.87 EPS next 5Y- ROE- 52W Range5.22 - 19.47 Perf YTD-9.10%
Dividend- P/FCF- EPS past 5Y35.60% ROI- 52W High-63.59% Beta1.08
Dividend %- Quick Ratio17.70 Sales past 5Y- Gross Margin- 52W Low35.75% ATR0.31
Employees32 Current Ratio17.70 Sales Q/Q- Oper. Margin- RSI (14)39.53 Volatility4.05% 4.19%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.43 Prev Close7.01
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume271.56K Price7.09
Recom1.80 SMA20-5.28% SMA50-10.78% SMA200-25.80% Volume115,761 Change1.14%
Nov-05-20Initiated Alliance Global Partners Buy $25
Dec-06-17Initiated B. Riley FBR, Inc. Buy $2.75
Oct-23-17Resumed ROTH Capital Buy $6
Sep-14-17Initiated Maxim Group Buy $3
Aug-25-16Initiated ROTH Capital Buy $5
Feb-29-16Initiated H.C. Wainwright Buy $8
Oct-15-15Initiated FBR Capital Outperform $12
Oct-01-14Initiated MLV & Co Buy $16
Jul-22-14Initiated Canaccord Genuity Buy $16
Apr-06-21 09:07AM  
Apr-05-21 01:23AM  
Mar-31-21 06:11PM  
Mar-25-21 09:00AM  
Mar-24-21 07:30AM  
Mar-11-21 07:00AM  
Mar-03-21 07:00AM  
Mar-02-21 07:30AM  
Feb-11-21 07:15AM  
Feb-10-21 07:15AM  
Jan-20-21 07:00AM  
Jan-13-21 07:00AM  
Dec-29-20 08:30AM  
Dec-23-20 05:45PM  
Dec-17-20 05:45PM  
Dec-09-20 05:45PM  
Dec-08-20 08:00AM  
Dec-07-20 08:30AM  
Dec-03-20 07:00AM  
Dec-02-20 08:49PM  
Dec-01-20 07:00AM  
Nov-23-20 07:00AM  
Nov-20-20 05:45PM  
Nov-19-20 07:30AM  
Nov-16-20 07:00AM  
Nov-13-20 05:45PM  
Nov-11-20 08:00AM  
Nov-04-20 12:21PM  
Oct-29-20 11:30AM  
Oct-28-20 07:00AM  
Oct-22-20 05:45PM  
Oct-21-20 08:04AM  
Oct-14-20 07:00AM  
Oct-09-20 06:37AM  
Oct-08-20 05:45PM  
Oct-06-20 07:00AM  
Oct-02-20 05:45PM  
Sep-23-20 07:00AM  
Sep-14-20 07:00AM  
Sep-10-20 07:00AM  
Aug-31-20 06:05PM  
Aug-28-20 11:30AM  
Aug-26-20 08:48AM  
Aug-12-20 11:30AM  
Aug-10-20 02:30PM  
Aug-04-20 05:45PM  
Aug-03-20 11:54AM  
Jul-28-20 05:50PM  
Jul-27-20 11:30AM  
Jul-23-20 12:00PM  
Jul-21-20 08:57AM  
Jul-20-20 10:32AM  
Jul-15-20 07:03AM  
Jul-09-20 11:30AM  
Jul-08-20 09:05AM  
Jun-19-20 05:15PM  
Jun-17-20 11:30AM  
Jun-16-20 11:30PM  
Jun-15-20 11:29PM  
Jun-12-20 08:43AM  
Jun-09-20 08:47AM  
Jun-04-20 09:45PM  
Jun-03-20 09:53AM  
Apr-24-20 05:15PM  
Apr-21-20 11:35PM  
Apr-16-20 07:00AM  
Apr-12-20 09:02AM  
Mar-06-20 10:56AM  
Mar-05-20 07:30AM  
Feb-26-20 07:33AM  
Feb-25-20 09:33AM  
Feb-21-20 07:30AM  
Feb-13-20 08:03AM  
Feb-05-20 05:50PM  
Jan-30-20 05:45PM  
Jan-13-20 12:00PM  
Jan-07-20 07:03AM  
Jan-03-20 11:30AM  
Jan-02-20 09:29AM  
Dec-22-19 05:08PM  
Dec-09-19 06:10AM  
Dec-07-19 08:35AM  
Dec-01-19 09:30AM  
Nov-20-19 09:00AM  
Nov-07-19 04:05PM  
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.